| Active Not Recruiting | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma NCT05010629 | Glenn J. Hanna | Phase 2 |
| Completed | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511 | Mayo Clinic | Phase 2 |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Completed | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01816984 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating NCT01847326 | University of Chicago | Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer NCT01613768 | University of Washington | Phase 2 |
| Terminated | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137 | Stanford University | Phase 1 |
| Completed | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177 | University of Washington | Phase 1 |
| Withdrawn | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck C NCT01332279 | Fox Chase Cancer Center | Phase 1 |
| Completed | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr NCT01316757 | Fox Chase Cancer Center | Phase 2 |
| Completed | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For NCT01155609 | University of Washington | N/A |
| Completed | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck NCT01044433 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance NCT01637194 | Fox Chase Cancer Center | Phase 1 |
| Terminated | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00507767 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck NCT00470496 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer NCT00126607 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer NCT00114283 | National Cancer Institute (NCI) | Phase 2 |
| Completed | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00095628 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland NCT00095563 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Ad NCT00077428 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the NCT00081211 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497 | National Cancer Institute (NCI) | N/A |
| Completed | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck NCT00033618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca NCT00055770 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |